Posted inBiotechnology
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
Jazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.



